La cadena de opciones muestra datos clave de las opciones de acciones de Monte Rosa Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Monte Rosa Therapeutics..

Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa, Cadena de Opciones

Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics Inc

<ul>
<li>INTC</li>
<li>TSLA</li>
<li>AAPL</li>
<li>DJT</li>
<li>MSTR</li>
<li>NVDA</li>
<li>META</li>
<li>QQQ</li>
<li>RIVN</li>
<li>AMD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

INTC

MSTR

NVDA

RIVN

TSLA

Top 10 Trending Stocks On WallStreetBets As Of January 17, 2025 (Via Swaggy Stocks)

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher ahead of the upcoming inauguration of President-elect Trump.

Evercore ISI Group analyst Amit Daryanani maintains Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Outperform and lowers the price target from $43 to $40.

News

Price Target

Analyst Ratings

Evercore ISI Group Maintains Outperform on Sensata Technologies, Lowers Price Target to $40

Evercore ISI Group analyst Glenn Schorr maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Outperform and raises the price target from $25 to $26.

Evercore ISI Group Maintains Outperform on Blue Owl Cap, Raises Price Target to $26

Credo Technology Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NYSE">CRDO</a>) short percent of float has risen 11.15% since its last report. The company recently reported that it has 7.94 million shares sold short, which is 5.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Credo Technology Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737126921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Credo Technology Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Credo Technology Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Credo Technology Group's peer group average for short interest as a percentage of float is 5.21%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CRDO

How Is The Market Feeling About Credo Technology Group?

Jones Lang LaSalle's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) short percent of float has risen 13.82% since its last report. The company recently reported that it has 696 thousand shares sold short, which is 1.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Jones Lang LaSalle Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737126916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Jones Lang LaSalle has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Jones Lang LaSalle's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Jones Lang LaSalle's peer group average for short interest as a percentage of float is 5.92%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Jones Lang LaSalle's Recent Short Interest

Biden administration officials are racing to finalize nearly $40 billion in semiconductor funding before leaving office, marking what The Economist calls &#8220;arguably the biggest single bet on industrial policy by the government in decades.&#8221;
The Department of Commerce&#8217;s aggressive disbursement of CHIPS Act money has already reshaped America&#8217;s semiconductor landscape. According to Commerce Secretary Gina Raimondo, private investments have reached $450 billion, with manufacturing giants like Intel, TSMC and Samsung breaking ground on new facilities nationwide.
&#8220;I see it as getting the job done efficiently with taxpayer money,&#8221; Raimondo told The Economist, dismissing concerns about the rushed timeline. The funding sprint comes as President-elect Donald Trump, who called CHIPS a &#8220;bad deal,&#8221; <a href="https://www.benzinga.com/24/12/42420201/trumps-return-threatens-billions-in-us-chip-investment-from-taiwan-samsung">prepares to take office next week</a>.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
Early returns suggest the gamble is paying off. The Semiconductor Industry Association reports that America&#8217;s share of advanced chip production, nearly nonexistent in 2022, is projected to reach 28% of global capacity by 2032.
The funding has helped narrow a crucial cost gap. Historically, building and operating chip plants in America cost 30% more than in Asia. CHIPS money and tax incentives have made U.S. manufacturing more competitive.
A Tech Target report issued this week notes that six companies have secured the largest awards: <a href="https://www.benzinga.com/news/large-cap/24/11/42187787/intel-to-receive-nearly-8-billion-in-federal-funding-under-chips-act-for-us-expansion">Intel ($7.9 billion)</a>, TSMC ($6.6 billion), Micron ($6.2 billion), Samsung ($4.7 billion), Texas Instruments ($1.6 billion) and GlobalFoundries ($1.5 billion). To receive the funds, companies must meet specific production milestones.
See Also: With 100+ historic trademark victories, this company holds IP for some of the highest-grossing characters in history. Now, they've propelled these icons into the future using next-gen patented AR, VR, and AI technology. <a href="https://www.benzinga.com/money/elf-labs-1">There&#8217;s now a limited window for investors to claim shares at just $2/share with $980 minimum—but the clock is ticking.</a>
Industry experts warn that maintaining momentum requires long-term commitment. &#8220;We should be sober about how challenging it will be to keep the investment going,&#8221; Chris Miller, author of &#8220;Chip War,&#8221; told The Economist. China continues massive investments in its semiconductor industry, while companies like TSMC spend over $30 billion annually on manufacturing upgrades.
The program&#8217;s success has revitalized the Commerce Department&#8217;s role in industrial policy. Once housing the world&#8217;s largest office building, the department had faded into handling routine trade missions before CHIPS restored its strategic importance.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

The 'Biggest Single Bet' In Decades: America's $40 Billion Gamble On Chips Pays Off

Aon's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) short percent of float has risen 6.47% since its last report. The company recently reported that it has 4.57 million shares sold short, which is 2.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Aon Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737126911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Aon has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Aon's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Aon's peer group average for short interest as a percentage of float is 2.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Aon?

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 5 years by 11.56% on an annualized basis producing an average annual return of 24.04%. Currently, Blackstone has a market capitalization of $139.43 billion. 
Buying $100 In BX: If an investor had bought $100 of BX stock 5 years ago, it would be worth $293.59 today based on a price of $179.59 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737126907_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 300 points on Friday.
Following the market opening Friday, the Dow traded up 0.76% to 43,482.39 while the NASDAQ rose 1.36% to 19,601.89. The S&amp;P 500 also rose, gaining, 0.88% to 5,989.58.
Check This Out: <a href="https://www.benzinga.com/25/01/43051869/top-3-defensive-stocks-that-could-blast-off-this-quarter">Top 3 Defensive Stocks That Could Blast Off This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares surged by 1.4% on Friday.
In trading on Friday, utilities shares fell by 0.1%.
Top Headline
U.S. industrial production rose by 0.9% in December, topping market estimates of a 0.3% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares shot up 80% to $36.99 after the company announced it resolved its Nasdaq delisting notice and is now achieving compliance with the listing standards.</li>
<li>Shares of Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>)got a boost, surging 45% to $2.8792 after the company announced expansion into the Brazilian market as part of its strategy to grow its international footprint.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares were also up, gaining 43% to $0.3058.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Scorpius Holdings, Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NYSE">SCPX</a>) shares dropped 26% to $0.2783 after the company announced its board approved a 1-for-20 reverse stock split.</li>
<li>Shares of BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) were down 25% to $0.0915 after the company announced a dilutive change in the ratio of American depositary shares to ordinary shares. The proposed exchange ratio is equivalent to a 1-for-40 basis reverse stock split.</li>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) was down, falling 17% to $0.1419.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $78.59 while gold traded down 0.2% at $2,745.00.
Silver traded down 1.7% to $31.185 on Friday, while copper fell 1.3% to $4.3825.
Euro zone
European shares were higher today. The eurozone's STOXX 600 surged 0.8%, Germany's DAX 40 gained 1.2% and France's CAC 40 gained 1.2%. Spain's IBEX 35 Index rose 0.7%, while London's FTSE 100 gained 1.5%.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 falling 0.31%, China's Shanghai Composite Index gaining 0.18%, Hong Kong's Hang Seng Index climbing 0.31% and India's BSE Sensex falling 0.55%.
Economics
<ul>
<li>U.S. industrial production rose by 0.9% in December, topping market estimates of a 0.3% increase.</li>
<li>Housing starts rose by 15.8% from the previous month to an annualized rate of 1.499 million units in December.</li>
<li>Building permits declined by 0.7% to an annualized rate of 1.483 million in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43055377/how-to-earn-500-a-month-from-3m-stock-ahead-of-q4-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q4 Earnings</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Markets

AEON

BLRX

NUKK

SCPX

Dow Jumps Over 300 Points; US Industrial Production Beats Estimates

Cantor Fitzgerald analyst Andres Sheppard downgrades Polestar Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) from Overweight to Neutral.

Downgrades

PSNY

Cantor Fitzgerald Downgrades Polestar Automotive to Neutral

D. Boral Capital analyst Jason Kolbert maintains CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) with a Buy and maintains $12 price target.

CARM

D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $12 Price Target

WRBY

Warby Parker shares are trading lower after Evercore ISI Group downgraded the stock from Outperform to In-Line and announced a price target of $23.

Life360 shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $52 to $55.

<a href="https://www.washingtonpost.com/politics/2025/01/17/titktok-ban-supreme-court-decision-ruling/" title="https://www.washingtonpost.com/politics/2025/01/17/titktok-ban-supreme-court-decision-ruling/">https://www.washingtonpost.com/politics/2025/01/17/titktok-ban-supreme-court-decision-ruling/</a>

Government

Politics

Legal

General

SNAP

'Supreme Court Upholds TikTok Ban-Or-Sale Law' - Washington Post

Cloud computing platform designer ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) shares are trading higher on Friday. The company announced an agreement to acquire Cuein, a firm focused on<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43054434/servicenow-accelerates-agentic-ai-roadmap-with-acquisition-of-ai-native-conversation-data-analysis" rel="noreferrer noopener"> AI-based conversation data analysis</a>.
Belmont, California-based Cuein was co-founded in 2021 by Mayukh Bhaowal and Vignesh Ganapathy. Cuein is backed by Lightspeed Venture Partners, Khosla Ventures, and Webb Investment Network.
Financial terms of the deal were not disclosed. This acquisition is designed to strengthen the functionality of ServiceNow&#8217;s AI agents, enabling them to more effectively analyze customer interactions and derive valuable insights from various communication platforms, such as chat, email, and phone.
ServiceNow intends to incorporate Cuein&#8217;s AI technology into its platform, enhancing decision-making processes and elevating customer service experiences.
By analyzing fragmented customer data, Cuein will enable companies to deliver more intelligent, cohesive service solutions.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/43054401" rel="noreferrer noopener">Duolingo&#8217;s AI-Powered China Surge Impresses Bullish Analyst</a>
&#8220;ServiceNow is at the forefront of the agentic AI revolution, redefining what human-centered AI can achieve across the enterprise, and the acquisition of Cuein is essential to our vision of creating more integrated, intelligent systems that connect AI agents, data, and workflows,&#8221; said Dorit Zilbershot, group vice president of AI Experiences and Innovation at ServiceNow.
By incorporating Cuein&#8217;s features, ServiceNow anticipates enhancing its AI agents&#8217; ability to quickly learn and adapt, leading to improved customer results.
The acquisition is expected to be completed in the first quarter of 2025. ServiceNow held $5.3 billion in cash and <a href="https://www.benzinga.com/pressreleases/24/10/b41500566/servicenow-reports-third-quarter-2024-financial-results" target="_blank" rel="noreferrer noopener">equivalents as of September 30, 2024</a>.
Price Action: NOW shares are trading higher by 0.84% at $1,066 at the last check Friday.
Image: Shutterstock.

Equities

ServiceNow Expands AI Arsenal With Cuein Acquisition: Details

Cantor Fitzgerald analyst Thomas Blakey initiates coverage on Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Neutral rating and announces Price Target of $87.

Initiation

Cantor Fitzgerald Initiates Coverage On Zoom Communications with Neutral Rating, Announces Price Target of $87

Wipro shares are trading higher after the company reported better-than-expected Q3 financial results and announced an interim dividend.

JP Morgan analyst Bill Peterson maintains United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) with a Overweight and lowers the price target from $44 to $40.

JP Morgan Maintains Overweight on United States Steel, Lowers Price Target to $40

Cantor Fitzgerald analyst Thomas Blakey initiates coverage on Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Neutral rating and announces Price Target of $264.

TEAM

Cantor Fitzgerald Initiates Coverage On Atlassian with Neutral Rating, Announces Price Target of $264

Monte Rosa Therapeutics ( ($GLUE) ) just unveiled an announcement. Monte Rosa Therapeutics has shared promising interim results from its Phase 1/2 ...

Monte Rosa Highlights Promising Results in Cancer Study

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monte Rosa Therapeutics (GLUE – Research Report), Ab...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insulet (PODD – Research Report) and Monte Rosa Ther...

Analysts' Top Healthcare Picks: Insulet (PODD), Monte Rosa Therapeutics (GLUE)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veeva Systems (VEEV – Research Report), Monte Rosa T...

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Monte Rosa Therapeutics (GLUE) and CAMP4 Therapeutics Corporation (CAMP)

Monte Rosa Therapeutics (GLUE) announced the closing of the Company's previously announced global exclusive development and commercialization licen...

Monte Rosa announces closing of global license agreement with Novartis

Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase...

Monte Rosa Therapeutics presents preclinical data on CDK2 degrader

Tracking Baker Brothers Portfolio - Q3 2024 Update

Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics (GLUE) to Equal Weight from Overweight with a price arget of $11, down from $1...

Monte Rosa downgraded to Equal Weight from Overweight at Wells Fargo

Monte Rosa Therapeutics ( ($GLUE) ) has provided an announcement. Monte Rosa Therapeutics announced its anticipated milestones for 2025, including ...

Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength

Monte Rosa Therapeutics (GLUE) outlined anticipated 2025 milestones ahead of its participation in the 43rd Annual J.P. Morgan Healthcare Conference...

Monte Rosa Therapeutics provide corporate update, key milestones 2025

ABCL

ABSI

ACAD

ALGS

ALKS

ARGNF

ARGX

AVTE

BCYC

BEIGF

BGNE

BMEA

CAMP

CERS

DNLI

EWTX

GEHC

GLUE

HOOK

IGMS

IMCR

IMTX

INCY

INSM

KALA

KNSA

KYMR

MDGL

NRIX

PODD

RARE

REPL

RVMD

RYTM

SGMT

SMMT

STOK

TCRX

TRDA

TSVT

VEEV

VTVT

Press Releases

"Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments"

Earnings

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

Health Care

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Management

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Comments

Monte Rosa Therapeutics

Monte Rosa Therapeutics (GLUE) Opciones

Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL